| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| gabapentin | Capsule, hard | 300 mg | Current | Limited Availability | Manufacturing | 25/10/2024 |
| sumatriptan succinate | Tablet, film coated | 140 mg | Current | Limited Availability | Manufacturing | 25/10/2024 |
| azithromycin dihydrate | Tablet, film coated | 524.1 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 25/10/2024 |
| dutasteride~tamsulosin hydrochloride | Capsule, modified release | 500 microgram~400 microgram | Current | Limited Availability | Manufacturing | 25/10/2024 |
| valsartan~hydrochlorothiazide | Tablet, film coated | 320 mg~25 mg | Current | Limited Availability | Manufacturing | 25/10/2024 |
| esomeprazole magnesium dihydrate | Tablet, enteric coated | 21.75 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 25/10/2024 |
| clonidine hydrochloride | Tablet | 100 microgram | Anticipated | Available | Manufacturing | 25/10/2024 |
| fluorouracil | Injection, solution | 50 mg/mL | Resolved | Available | Manufacturing | 25/10/2024 |
| verapamil hydrochloride | Tablet, modified release | 180 mg | Current | Limited Availability | Manufacturing | 25/10/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 1.54 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 25/10/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | .77 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 25/10/2024 |
| oxycodone hydrochloride | Capsule, hard | 5 mg | Resolved | Available | Manufacturing | 25/10/2024 |
| nizatidine | Capsule | 300 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 25/10/2024 |
| flecainide acetate | Injection, solution | 10 mg/mL | Anticipated | Available | Manufacturing | 24/10/2024 |
| topiramate | Tablet, film coated | 200 mg | Anticipated | Available | Manufacturing | 24/10/2024 |
| gliclazide | Tablet, modified release | 30 mg | Resolved | Available | Manufacturing | 24/10/2024 |
| donepezil hydrochloride | Tablet, film coated | 5 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 24/10/2024 |
| bisoprolol fumarate | Tablet | 5 mg | Current | Unavailable | Manufacturing | 24/10/2024 |
| bicalutamide | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 24/10/2024 |
| azithromycin dihydrate | Tablet, film coated | 524.05 mg | Current | Limited Availability | Manufacturing | 24/10/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Current | Limited Availability | Manufacturing | 24/10/2024 |
| quetiapine fumarate | Tablet, film coated | 28.78 mg | Anticipated | Available | Manufacturing | 24/10/2024 |
| rizatriptan benzoate | Tablet, orally disintegrating | 14.53 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 24/10/2024 |
| simvastatin | Tablet, film coated | 40 mg | Current | Unavailable | Manufacturing | 24/10/2024 |
| citalopram hydrobromide | Tablet, film coated | 49.98 mg | Current | Unavailable | Manufacturing | 24/10/2024 |
| citalopram hydrobromide | Tablet, film coated | 49.98 mg | Anticipated | Available | Manufacturing | 24/10/2024 |
| mitomycin | Injection, powder for | 20 mg | Resolved | Available | Manufacturing | 24/10/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 24/10/2024 |
| emtricitabine~tenofovir disoproxil maleate | Tablet, film coated | 200 mg~300 mg | Current | Unavailable | Manufacturing | 24/10/2024 |
| prochlorperazine maleate | Tablet, uncoated | 5 mg | Current | Unavailable | Commercial Changes / Commercial viability | 24/10/2024 |
| nebivolol hydrochloride | Tablet | 1.363 mg | Current | Unavailable | Manufacturing | 24/10/2024 |
| betahistine dihydrochloride | Tablet, uncoated | 16 mg | Current | Limited Availability | Manufacturing | 24/10/2024 |
| cinacalcet hydrochloride | Tablet | 99.191 mg | Current | Limited Availability | Manufacturing | 24/10/2024 |
| dosulepin (dothiepin) hydrochloride | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 24/10/2024 |
| azacitidine | Injection, powder for | 100 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/10/2024 |
| estradiol | Drug delivery system, transdermal | 1.56 mg | Current | Limited Availability | Manufacturing | 24/10/2024 |
| flecainide acetate | Tablet | 50 mg | Current | Unavailable | Manufacturing | 24/10/2024 |
| bortezomib | Injection, solution | 3.5 mg | Current | Unavailable | Manufacturing | 24/10/2024 |
| paracetamol | Tablet, modified release | 665 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 24/10/2024 |
| norethisterone acetate~estradiol | Drug delivery system, transdermal | 4.8 mg~.512 mg | Current | Limited Availability | Manufacturing | 24/10/2024 |
| metformin hydrochloride | Tablet, film coated | 850 mg | Current | Unavailable | Manufacturing | 24/10/2024 |
| pravastatin sodium | Tablet, uncoated | 40 mg | Current | Limited Availability | Manufacturing | 24/10/2024 |
| medronic acid | Injection, powder for | 10 mg | Current | Limited Availability | Manufacturing | 23/10/2024 |
| donepezil hydrochloride | Tablet, film coated | 10 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 23/10/2024 |
| levetiracetam | Tablet, film coated | 250 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 23/10/2024 |
| bisoprolol fumarate | Tablet | 2.5 mg | Current | Unavailable | Manufacturing | 23/10/2024 |
| bisoprolol fumarate | Tablet | 10 mg | Anticipated | Available | Manufacturing | 23/10/2024 |
| irbesartan | Tablet, film coated | 300 mg | Resolved | Available | Manufacturing | 23/10/2024 |
| methotrexate | Injection, solution | 100 mg/mL | Current | Unavailable | Manufacturing | 23/10/2024 |
| epirubicin hydrochloride | Injection, concentrated | 200 mg | Current | Unavailable | Manufacturing | 23/10/2024 |
| betahistine dihydrochloride | Tablet | 24 mg | Current | Limited Availability | Unexpected increase in consumer demand | 23/10/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Manufacturing | 23/10/2024 |
| tenofovir disoproxil fumarate~emtricitabine | Tablet, film coated | 300 mg~200 mg | Current | Unavailable | Manufacturing | 23/10/2024 |
| tadalafil | Tablet, film coated | 10 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 23/10/2024 |
| lacosamide | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 23/10/2024 |
| lidocaine hydrochloride | Injection, solution | 400 mg | Current | Unavailable | Manufacturing | 23/10/2024 |
| amlodipine besilate~olmesartan medoxomil~hydrochlorothiazide | Tablet, film coated | 6.95 mg~40 mg~25 mg | Current | Unavailable | Manufacturing | 23/10/2024 |
| amoxicillin trihydrate | Oral Liquid, powder for | 114.82 mg/mL | Resolved | Available | Manufacturing | 23/10/2024 |
| cytarabine | Injection, solution | 100 mg | Current | Limited Availability | Unexpected increase in consumer demand | 22/10/2024 |
| papaverine hydrochloride | Injection, solution | 12 mg/mL | Current | Limited Availability | Manufacturing | 22/10/2024 |
| clonidine hydrochloride | Tablet, uncoated | 100 microgram | Resolved | Available | Manufacturing | 22/10/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~5.198 mg | Resolved | Available | Manufacturing | 22/10/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~20.791 mg | Current | Limited Availability | Manufacturing | 22/10/2024 |
| levetiracetam | Injection, concentrated | 500 mg | Resolved | Available | Manufacturing | 22/10/2024 |
| pemetrexed disodium | Injection, powder for | 1102.9 mg | Current | Unavailable | Manufacturing | 22/10/2024 |
| meloxicam | Capsule, hard | 15 mg | Anticipated | Available | Manufacturing | 22/10/2024 |
| cisplatin | Injection, concentrated | 1 mg/mL | Current | Unavailable | Unexpected increase in consumer demand | 22/10/2024 |
| rasagiline mesilate | Tablet | 1.56 mg | Current | Limited Availability | Manufacturing | 22/10/2024 |
| celecoxib | Capsule, hard | 100 mg | Resolved | Available | Manufacturing | 22/10/2024 |
| solifenacin succinate | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 22/10/2024 |
| solifenacin succinate | Tablet, film coated | 10 mg | Current | Unavailable | Manufacturing | 22/10/2024 |
| lacosamide | Tablet, film coated | 100 mg | Resolved | Available | Manufacturing | 22/10/2024 |
| modafinil | Tablet, uncoated | 100 mg | Resolved | Available | Manufacturing | 22/10/2024 |
| quinagolide hydrochloride | Tablet, uncoated | .0819 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 22/10/2024 |
| clarithromycin | Oral Liquid, powder for | 50 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 22/10/2024 |
| norethisterone~ethinylestradiol | Tablet, uncoated | 1 mg~36 microgram | Current | Limited Availability | Manufacturing | 22/10/2024 |
| clonidine hydrochloride | Tablet, uncoated | 150 microgram | Resolved | Available | Manufacturing | 22/10/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 54 mg | Current | Limited Availability | Manufacturing | 22/10/2024 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 1.82 mg/mL | Anticipated | Available | Manufacturing | 21/10/2024 |
| topiramate | Tablet, film coated | 25 mg | Anticipated | Available | Manufacturing | 21/10/2024 |
| pentetic acid | Injection, powder for | 5 mg | Current | Limited Availability | Manufacturing | 21/10/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~10.396 mg | Current | Limited Availability | Manufacturing | 21/10/2024 |
| rosuvastatin calcium~ezetimibe | Tablet~Tablet, film coated | 20.791 mg~10 mg | Current | Limited Availability | Manufacturing | 21/10/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~5.198 mg | Current | Limited Availability | Manufacturing | 21/10/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~10.396 mg | Resolved | Available | Manufacturing | 21/10/2024 |
| paclitaxel | Injection, concentrated | 300 mg | Resolved | Available | Manufacturing | 21/10/2024 |
| milrinone | Injection, concentrated | 10 mg | Resolved | Available | Manufacturing | 21/10/2024 |
| cefepime hydrochloride monohydrate | Injection, powder for | 1189.2 mg | Current | Limited Availability | Manufacturing | 21/10/2024 |
| temozolomide | Capsule, hard | 20 mg | Anticipated | Available | Manufacturing | 21/10/2024 |
| benzatropine mesilate | Injection | 1 mg/mL | Anticipated | Available | Manufacturing | 21/10/2024 |
| hydromorphone hydrochloride | Injection, solution | 2 mg | Current | Limited Availability | Manufacturing | 21/10/2024 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.751 mg | Anticipated | Available | Manufacturing | 21/10/2024 |
| lenalidomide | Capsule, hard | 5 mg | Resolved | Available | Unexpected increase in consumer demand | 21/10/2024 |
| levothyroxine sodium | Tablet | 50 microgram | Current | Unavailable | Manufacturing | 21/10/2024 |
| clindamycin hydrochloride | Solution | 10 mg/mL | Current | Unavailable | Manufacturing | 21/10/2024 |
| sodium pertechnetate(99mTc) | Injection, solution | 20 GBq | Resolved | Available | Manufacturing | 21/10/2024 |
| balsalazide sodium | Capsule | 750 mg | Resolved | Available | Commercial Changes / Commercial viability | 21/10/2024 |
2024年10月29日